Cooper Consumer Health
European consumer healthcare company focused on development, manufacture and distribution of over-the-counter (OTC) self-care products. Operates multiple European manufacturing sites and a central R&D hub, manages a broad branded product portfolio and a pan-European commercial footprint with local country teams. Reported metrics include ~€1.1 billion net revenue, ~1,800 employees, five manufacturing sites, one R&D centre and multiple regional headquarters.
Industries
N/A
Nr. of Employees
small (1-50)
Cooper Consumer Health
Products
OTC self-care product portfolio (personal care, essential health, wellbeing solutions)
A broad portfolio of over-the-counter self-care products across personal care, wound care/antiseptics, vitamins/minerals and wellbeing categories marketed across European pharmacies and retailers.
OTC self-care product portfolio (personal care, essential health, wellbeing solutions)
A broad portfolio of over-the-counter self-care products across personal care, wound care/antiseptics, vitamins/minerals and wellbeing categories marketed across European pharmacies and retailers.
Services
End-to-end development of OTC/self-care formulations and product innovation support.
Production and contract manufacturing across multiple European manufacturing sites to support branded OTC product supply and scale.
Pan-market distribution, pharmacy activation, local commercial teams and co-marketing support to deploy product portfolios across Europe.
S&OP processes, procurement management and logistics to maintain product availability across markets.
Regulatory strategy, market-access support and vigilance management including adverse-event processing and reporting.
E-commerce strategy, digital marketing and analytics to support online growth and omnichannel execution.
End-to-end development of OTC/self-care formulations and product innovation support.
Production and contract manufacturing across multiple European manufacturing sites to support branded OTC product supply and scale.
Pan-market distribution, pharmacy activation, local commercial teams and co-marketing support to deploy product portfolios across Europe.
S&OP processes, procurement management and logistics to maintain product availability across markets.
Regulatory strategy, market-access support and vigilance management including adverse-event processing and reporting.
E-commerce strategy, digital marketing and analytics to support online growth and omnichannel execution.
Expertise Areas
- OTC and consumer healthcare product development
- GMP manufacturing and contract manufacturing for OTC products
- Pan-European distribution and pharmacy channel management
- Regulatory compliance and pharmacovigilance
Key Technologies
- E-commerce platforms
- Web analytics and tracking
- Quality management systems (QMS)
- Pharmacovigilance reporting systems
News & Updates
Strategic partnership for distribution and commercialisation of the company's self-care portfolio in Central and Eastern Europe (effective 1 January 2025).
Announcement of commercial launch of operations in Germany with local teams supporting DACH market entry (go‑live 1 January 2025).
Completion of the acquisition of an OTC business including ~200 brands, two manufacturing sites and an R&D centre (announcement dated 3 July 2024).
Co‑marketing and distribution go‑live for a nicotine-replacement therapy portfolio across several European markets (commercial operations commencing 1 December 2025).
Completed acquisition of an OTC business that expanded product portfolio, added manufacturing sites and an R&D centre, doubling company revenue scale.
Strategic partnership for distribution and commercialisation of the company's self-care portfolio in Central and Eastern Europe (effective 1 January 2025).
Announcement of commercial launch of operations in Germany with local teams supporting DACH market entry (go‑live 1 January 2025).
Completion of the acquisition of an OTC business including ~200 brands, two manufacturing sites and an R&D centre (announcement dated 3 July 2024).
Co‑marketing and distribution go‑live for a nicotine-replacement therapy portfolio across several European markets (commercial operations commencing 1 December 2025).
Completed acquisition of an OTC business that expanded product portfolio, added manufacturing sites and an R&D centre, doubling company revenue scale.